Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) May 2025

Why Investors Should Consider Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP)

DON'T MISS THIS OPPORTUNITY

A Strategic Pivot into High-Growth Sectors

Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) is undergoing a transformative shift its origins as a biopharmaceutical company to a diversified entity embracing cutting-edge technologies. The company's recent initiatives include the launch of the COEP Venture Group, aimed at investing in disruptive technologies such as artificial intelligence (AI) and robotic process automation (RPA) . This strategic pivot positions Coeptis to capitalize on high-growth sectors beyond traditional pharmaceuticals.(investors.coeptistx.com, stockinsights.ai)

Innovative Cell Therapy Platforms

Despite its diversification, Coeptis continues to advance its biopharmaceutical

endeavors. The company is developing innovative cell therapy platforms for cancer treatment, including CD38-GEAR-NK, an autologous, gene-edited natural killer (NK) cell-based therapeutic, and CD38-Diagnostic, an in vitro screening tool designed to identify patients likely to benefit from targeted anti-CD38 monoclonal antibody therapies . These platforms have the potential to disrupt conventional treatment paradigms and improve patient outcomes.(Nasdaq, www.alphaspread.com, Annual Reports)

Strategic Merger with Z Squared Inc.

In a significant move, Coeptis has entered into a definitive merger agreement with

Z Squared Inc., a Dogecoin mining company. This merger will make Z Squared a wholly-owned subsidiary of Coeptis, with plans to spin out its biopharmaceutical operations and rebrand as Z Squared, Inc. The combined company aims to enhance Dogecoin mining capabilities and capitalize on the growing digital asset market .(Nasdaq)

Robust Financial Backing

Coeptis has demonstrated strong financial support through successful funding rounds. The company recently closed a $10 million Series A Preferred financing round, reinforcing its commitment to technological innovation and AI integration (PR Newswire). Additionally, a prior $4.3 million Series A Preferred offering was led by CJC Investment Trust, an entity controlled by board member Christopher Calise (PR Newswire).

INVESTMENT ALERT

Investment Highlights

• Diversified Portfolio: Transitioning into high-growth sectors like AI, RPA, and digital assets.

• Innovative Therapies: Developing next-generation cell therapy platforms for oncology.

• Strategic Partnerships: Merging with Z Squared Inc. to enter the cryptocurrency mining space.(Nasdaq)

• Financial Strength: Secured substantial funding to support growth and innovation initiatives.

BUY NOW

Call your Broker now!

Learn More

For more information, visit the Investor Relations page of Coeptis Therapeutics Holdings Inc.

---

DISCLAIMER

Snapmediagroup.net and Vanderbiltreport.com are owned and operated by SMG a US-based corporation. We have not received any compensation regarding the profiling of Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP). It is important to note that we do not own any shares in COEP: NASDAQ.